CN1692116A - 腺苷A2a受体拮抗剂 - Google Patents

腺苷A2a受体拮抗剂 Download PDF

Info

Publication number
CN1692116A
CN1692116A CNA02823782XA CN02823782A CN1692116A CN 1692116 A CN1692116 A CN 1692116A CN A02823782X A CNA02823782X A CN A02823782XA CN 02823782 A CN02823782 A CN 02823782A CN 1692116 A CN1692116 A CN 1692116A
Authority
CN
China
Prior art keywords
compound
alkyl
compounds
pharmaceutical composition
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA02823782XA
Other languages
English (en)
Chinese (zh)
Inventor
C·D·博伊尔
S·查卡拉曼尼尔
W·J·格林利
U·G·沙
夏岩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1692116A publication Critical patent/CN1692116A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CNA02823782XA 2001-11-30 2002-11-26 腺苷A2a受体拮抗剂 Pending CN1692116A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33434201P 2001-11-30 2001-11-30
US60/334,342 2001-11-30

Publications (1)

Publication Number Publication Date
CN1692116A true CN1692116A (zh) 2005-11-02

Family

ID=23306779

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA02823782XA Pending CN1692116A (zh) 2001-11-30 2002-11-26 腺苷A2a受体拮抗剂

Country Status (18)

Country Link
US (1) US6916811B2 (enExample)
EP (1) EP1448565B1 (enExample)
JP (2) JP4284182B2 (enExample)
KR (1) KR20050044593A (enExample)
CN (1) CN1692116A (enExample)
AR (1) AR037680A1 (enExample)
AT (1) ATE453647T1 (enExample)
AU (1) AU2002346503A1 (enExample)
CA (1) CA2468649C (enExample)
DE (1) DE60234951D1 (enExample)
ES (1) ES2336435T3 (enExample)
HU (1) HUP0402018A3 (enExample)
IL (1) IL161716A0 (enExample)
MX (1) MXPA04005209A (enExample)
PE (1) PE20030665A1 (enExample)
TW (1) TW200306837A (enExample)
WO (1) WO2003048165A1 (enExample)
ZA (1) ZA200404161B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112469722A (zh) * 2018-07-23 2021-03-09 百济神州有限公司 作为a2a受体拮抗剂的吡唑并三唑并嘧啶衍生物

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1283839B1 (en) * 2000-05-26 2005-04-20 Schering Corporation Adenosine a2a receptor antagonists
US6964288B2 (en) * 2001-07-06 2005-11-15 Ksaria Corporation Apparatus and method for automated preparation of an optical fiber
MY124864A (en) 2001-10-15 2006-07-31 Schering Corp Adenosine a2a receptor antagonists
BR0304963A (pt) * 2002-05-30 2004-09-28 King Pharmaceuticals Res & Dev Compostos, composição farmacêutica, e, métodos para modular a atividade de adenosina em um mamìfero, e para tratar um mamìfero sofrendo de ou suscetìvel às doenças
BR0317436A (pt) * 2002-12-19 2005-11-16 Schering Corp Usos de antagonistas do receptor a2a de adenosina
EP1678168B1 (en) * 2003-10-24 2012-07-11 Exelixis, Inc. P70s6 kinase modulators and method of use
HRP20070063T3 (hr) * 2003-10-28 2007-04-30 Schering Corporation POSTUPAK DOBIVANJA SUPSTITUIRANIH 5-AMINOPIRAZOLO[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PIRIMIDINA
US20060009504A1 (en) * 2003-12-19 2006-01-12 Schering Corporation Pharmaceutical compositions
JPWO2006132275A1 (ja) * 2005-06-07 2009-01-08 協和醗酵工業株式会社 運動障害の予防および／または治療剤
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
PE20080145A1 (es) * 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
US7723343B2 (en) 2007-03-30 2010-05-25 King Pharmaceuticals Research And Development, Inc. Adenosine A2A receptor antagonists
US8288397B2 (en) 2007-12-17 2012-10-16 Janssen Pharmaceutica Nv Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1
US12246013B2 (en) 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
CA2732521C (en) 2008-08-01 2017-11-07 Alpha Synergy Development, Inc. Vasoconstriction compositions and methods of use
TW201036614A (en) 2008-12-30 2010-10-16 Arqule Inc Substituted 1H-pyrazolo[3,4-d]pyrimidine-6-amine compounds
EP2414361A1 (en) 2009-03-31 2012-02-08 ArQule, Inc. Substituted heterocyclic compounds
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
CA2782872A1 (en) * 2009-12-17 2011-06-23 Alpha Synergy Development, Inc. Compositions and methods for ophthalmic delivery of nasal decongestants
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
US8999938B2 (en) 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
WO2020106560A1 (en) 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
KR20210093964A (ko) 2018-11-20 2021-07-28 머크 샤프 앤드 돔 코포레이션 치환된 아미노 트리아졸로피리미딘 및 아미노 트리아졸로피라진 아데노신 수용체 길항제, 제약 조성물 및 그의 용도
US12263171B2 (en) 2018-11-30 2025-04-01 Merck Sharp & Dohme Llc 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
CR20210271A (es) 2018-11-30 2021-07-14 Merck Sharp & Dohme Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso
DE102019116986A1 (de) 2019-06-24 2020-12-24 Helmholtz-Zentrum Dresden-Rossendorf E. V. Deuterierte 7-(3-(4-(2-([18F]Fluor)ethoxy)phenyl)propyl)-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amin-Derivate
JP2022540583A (ja) * 2019-07-17 2022-09-16 テオン セラピューティクス，インク． アデノシンａ２ａ受容体アンタゴニスト及びその使用
CN111825698B (zh) 2019-07-30 2021-10-15 杭州阿诺生物医药科技有限公司 腺苷受体拮抗剂
CN112574214B (zh) 2019-07-30 2021-09-28 杭州阿诺生物医药科技有限公司 腺苷受体拮抗剂的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
CA2144330A1 (en) 1993-07-27 1995-02-09 Fumio Suzuki A therapeutic agent for parkinson's disease
IT1277392B1 (it) * 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
US6448253B1 (en) * 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
US6921825B2 (en) * 1998-09-16 2005-07-26 King Pharmaceuticuals Research & Development, Inc. Adenosine A3 receptor modulators
EP1283839B1 (en) * 2000-05-26 2005-04-20 Schering Corporation Adenosine a2a receptor antagonists
BR0304963A (pt) * 2002-05-30 2004-09-28 King Pharmaceuticals Res & Dev Compostos, composição farmacêutica, e, métodos para modular a atividade de adenosina em um mamìfero, e para tratar um mamìfero sofrendo de ou suscetìvel às doenças
MY139344A (en) * 2003-04-23 2009-09-30 Schering Corp 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine a2a receptor antagonists

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112469722A (zh) * 2018-07-23 2021-03-09 百济神州有限公司 作为a2a受体拮抗剂的吡唑并三唑并嘧啶衍生物

Also Published As

Publication number Publication date
JP2005511699A (ja) 2005-04-28
HK1063780A1 (en) 2005-01-14
EP1448565B1 (en) 2009-12-30
WO2003048165A1 (en) 2003-06-12
TW200306837A (en) 2003-12-01
CA2468649A1 (en) 2003-06-12
MXPA04005209A (es) 2004-08-19
JP4284182B2 (ja) 2009-06-24
ATE453647T1 (de) 2010-01-15
US20030212059A1 (en) 2003-11-13
CA2468649C (en) 2009-03-10
KR20050044593A (ko) 2005-05-12
AR037680A1 (es) 2004-12-01
JP2008260776A (ja) 2008-10-30
AU2002346503A1 (en) 2003-06-17
EP1448565A1 (en) 2004-08-25
DE60234951D1 (de) 2010-02-11
PE20030665A1 (es) 2003-08-08
ZA200404161B (en) 2005-11-30
ES2336435T3 (es) 2010-04-13
HUP0402018A2 (hu) 2005-02-28
HUP0402018A3 (en) 2008-06-30
IL161716A0 (en) 2004-09-27
US6916811B2 (en) 2005-07-12

Similar Documents

Publication Publication Date Title
CN1692116A (zh) 腺苷A2a受体拮抗剂
US6653315B2 (en) Adenosine A2a receptor antagonists
JP4574112B2 (ja) アデノシンａ２ａレセプターアンタゴニスト
JP4284181B2 (ja) アデノシンＡ２ａレセプターアンタゴニスト
CN1319529C (zh) 作为大麻素－cb1受体配体的1h－1,2,4－三唑－3－酰胺衍生物
CN1122032C (zh) 用于治疗心血管疾病的新的取代吡唑衍生物
EP2038285B1 (en) Adenosine a2a receptor antagonists
EP1453836B1 (en) BICYCLIC [1,2,4] -TRIAZOLE ADENOSINE A2a RECEPTOR ANTAGONISTS
JP2008524213A (ja) 新規なピラゾール誘導体及びニコチン性アセチルコリン受容体のモジュレーターとしてのそれらの使用
JP2006525302A (ja) ニコチン性アセチルコリン受容体の正のモジュレーター
CN1135228C (zh) 用于治疗抑郁症的n-芳氧基乙基-吲哚基-烷基胺
JP2010536919A (ja) ノルエピネフリン、セロトニンまたはドーパミン再取り込み阻害剤として有用な３−アザビシクロ（４．１．０）ヘプタン誘導体
HK1064097B (en) Bicyclic [1,2,4] -triazole adenosine a2a receptor antagonists
HK1063780B (en) Adenosine a2a receptor antagonists
HK1064100B (en) Adenosine a 2a receptor antagonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20051102

C20 Patent right or utility model deemed to be abandoned or is abandoned